
XNK Therapeutics AB raises €12.75m
XNK Therapeutics said it will use the proceeds to accelerate an investigator-initiateed open Phase II study with its autologous NK cell-based...

CSL Behring files for MAA of haemophilia B gene therapy
Marburg-based CSL Behring has filed for accelerated EU marketing authorisation of Etranacogene dezaparvovec (EtranaDez), the first haemophilia B gene...

GeNeuro finds biologic against post-COVID syndrome
The results of a collaboration of GeNeuro with the FondaMental Foundation were presented at the Schizophrenia International Research Society (SIRS)...

Abliva decides on a SEK200m financing to fund Phase 2/3 study
Swedish Abliva is focussing on mitochondrial medicine, developing therapeutics for primary mitochondrial diseases, orphan indications of high unmet...

Enzymaster raises $45m in Series C round
The Series C financing round was led by Yuanbio Venture Capital with While Bayland Capital, Puhua Capital, C&D Emerging Capital, Hansoh...

International Vaccine Institute – IVI – will locate its European office in Stockholm
The International Vaccine Institute, IVI, is establishing itself outside South Korea for the first time. Last week, the Swedish Parliament ratified...

Transine Therapeutics Ltd closes £13.7m seed financing
Transine Therapeutics stressed it will use the proceeds to accelerate its preclinical pipeline of novel therapeutic RNAs (SINEUPs) capable of...